Good morning, Armchair Army,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
It has been a big year for Big Pharma M&A.
Around US$200 billion across 70 transactions in 2026.
(Eli Lilly has been the biggest spender with $32B across 11 transactions)
With patent cliffs coming and cash from GLP-1 sales, Pharma companies are looking to rebuild their R&D pipelines through acquisition.
Small biotechs do the early work → Big Pharma brings the money to take it further.
The circle of life.
But each acquisition carries a risk.
Sometimes it works…
Like Merck inheriting what became the mega-blockbuster Keytruda through its 2009 acquisition of Schering-Plough.
Sometimes it doesn’t…
Like Novartis this year, when the lead asset from the US$12 billion Avidity acquisition failed its pivotal Phase 3 trial.
You win some… you lose some.
That’s the name of the game.
But for CSL, it has been more ‘lose’ than ‘win’ recently.
The US$11.7 billion acquisition of Vifor in 2022 has been nothing short of a disaster.
A US$4.87 billion impairment on the acquisition this year indicates to the market that most of that value has been written off.
Yesterday, it announced a new co-development deal with Alentis for its claudin-1 fibrosis antibody, lixudebart.
Translation = they licensed another kidney asset.
US$355 million upfront.
US$1.2 billion in milestones.
Plus paying the cost of 4 more clinical trials.
… for 55% of the profits generated.
So…
Is this deal a win?
Or did they just get fleeced?
Let’s find out.
But first…
The Pulse Check
Emyria (ASX: EMD) published an interview with new US advisor Dr Shulkin, Former Secretary of Veterans Affairs. (EMD, held, armchair pick)
🪑 I’m about halfway through, and so far it’s been brilliant.
It’s clear how knowledgeable Dr Shulkin is in the US healthcare sector and how well he'll steward Emyria’s strategy in the region.
Worth a watch:
Tetratherix (ASX: TTX) received FDA 510(k) feedback on its submission for Tegenix (dental bone healing). It’s now back to TTX to answer questions on “chemical characterisation and labelling”. (TTX, held, Armchair Pick)
🪑 No 510(k) approval yet… but this is only a slight delay, and de-risks the larger approval questions around device classification, predicate choice and performance testing data.
Neurizon Therapeutics (ASX: NUZ) receives FDA feedback confirming the Phase 2/3 ALS trial may serve as a single registrational study for NUZ-001. (NUZ)
🪑 Approval still depends on the quality of the results, of course, but it’s still good to get this clarity.
Very nice update.
Enlitic (ASX: ENL) releases Ensight v2.3, expanding from 8 to 12 applications and integrating with Sectra. (ENL)
🪑 Sectra is the second major OEM integration (after Intelerad), which is important for customer friction and product use of its AI-based software and data integration product.
AFT Pharmaceuticals (ASX: AFP) affirms it's on track for NZ$300M in revenue for FY27, with operating profit guidance of NZ$28 to $32 million. (AFP)
🪑 You just know it’s a good quarter when you publish results six days into the month.
LTR Pharma (ASX: LTP) announces the first U.S. fulfilment of patient-specific ROXUS prescriptions through the telehealth platform Mavrox and Strive Pharmacy. (LTP)
🪑 Well done.
From Around the World
REPORT: Fears mount that Russia is covering up a lab plague leak. (AFR)
🪑 Oh no…
Genentech licenses Alector's preclinical blood-brain barrier asset in Parkinsons’ disease for US$100M upfront, US$1.17B in milestones. (Fierce Biotech)
Under the Microscope
Yesterday, CSL announced a co-development deal with private Swiss company Alentis for its claudin-1 fibrosis antibody, lixudebart.
Key targets?
A bunch of rare kidney and liver diseases, including FSGS.
(Source: CSL)
My shoot-from-the-hip, armchair take on this deal?
It was a GREAT deal.
… if you’re Alentis.
For CSL.
… you just got FLEECED.
CSL will pay:
US$355M upfront.
Up to US$1.2 billion in commercial milestones.
AND fund the remainder of a Phase 2 trial, a planned Phase 3 trial and TWO other Phase 2 trials, plus supporting development work.
In return, CSL gets:
55% of the global profits in the commercialised product, with Alentis keeping 45%.
CSL isn’t buying the molecule outright.
CSL isn’t buying Alentis’ pipeline.
It’s a partnership around lixudebart, not an acquisition of the company or its separate cancer-drug programs.
And CSL pays for the development program.
Four clinical trials.
But surely, Armchair, there must have been some seriously compelling data for CSL to pay such a price?
Well, dear reader, there was… but it wasn’t much.
A 26-patient interim read in Phase 2 for the kidney data and a 41-patient Phase 1b study in liver fibrosis.
While we don’t know what other data CSL saw behind closed doors…
It does look very expensive for a data package with limited human efficacy data.
Honestly, well done to the Alentis team for pulling it off.
What’s the strategy behind the acquisition?
Bill Mezzanotte, head of research and development at CSL, said:
“The deal was part of a broader strategy to balance internal research with external partnerships that can assist with development and eventual commercialisation.”
He also went on to say…
“We like this program because it has multiple disease opportunities in one product, giving us a chance to enhance our pipeline with a few different programs with one deal”
“CSL has committed to trying to do smart deals… We don’t want to overpay.”
I’m sorry, Bill, but this deal looks expensive.
This can happen in the thick of an M&A cycle, where a lot of the “good assets” have been earmarked and accounted for.
It’s called FOMO… and big pharma companies can get it too.
Ultimately, what will decide whether this acquisition is a “good deal” will be whether CSL can bring one or multiple products to market.
But for the amount paid (and the amount still committed to the program), I would have hoped for more than 55% of the revenue share IF you get there.
Any other takeaways from the deal?
It’s hard to look at a kidney deal (especially one that targets the rare kidney disease FSGS) and not think about Dimerix (ASX: DXB).
Dimerix is developing DMX-200, an oral drug designed to block an inflammatory pathway in the kidney.
Its Phase 3 program for FSGS reads out in mid-2028.
Three things about this CSL deal are relevant to Dimerix (in my opinion).
FIRST, this sets a new reference point for what Big Pharma will pay for a promising kidney asset.
DXB is trading at a A$141.1 million market cap.
CSL just committed US$355 million upfront for a partnership around an asset still in Phase 2.
SECOND, new competition may enter the arena.
CSL is funding a Phase 2 trial in FSGS.
If it works and eventually gets approved, DMX-200 could face a competitor in the market.
THIRD, Dimerix’s own “Acute Kidney Injury” acquisition looks very cheap in comparison.
A few months ago, Dimerix acquired DMX-652 for US$5M upfront and up to US$287 million in milestones, plus royalties.
This asset is ready for Phase 2 and initially targets the prevention of acute kidney injury after cardiac surgery.
Think of it like one step behind the asset that CSL just acquired.
BUT DXB picked this up for US$5M; CSL paid US$355M.
ALSO, this shows the potential value uplift a successful Phase 2 could generate for Dimerix.
Armchair Take
To be honest, I would have liked to have seen CSL invest in some of the promising Australian-listed biotech companies with their next acquisition.
King make, some winners in our sector.
Just like Pro Meidcus did with 4D Medical and EchoIQ.
Ultimately, only time will tell whether this deal is worth it.
But they’ve paid a high price for an early clinical opportunity with a lot still to prove.
See you all tomorrow,
The Armchair Analyst.
